<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809727</url>
  </required_header>
  <id_info>
    <org_study_id>HistopathSTH</org_study_id>
    <nct_id>NCT04809727</nct_id>
  </id_info>
  <brief_title>Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy</brief_title>
  <acronym>HSTH</acronym>
  <official_title>Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supracervical hysterectomy is widely common and had many complications either immediate or&#xD;
      delayed. In these patients bleeding, infection, chronic pelvic pain are common. In these&#xD;
      patients cervical biopsy was done and histopathological examinations were done to evaluate&#xD;
      the pathology in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Study design and settings: Cross sectional descriptive studies conducted from December&#xD;
           2017 till January 2021.&#xD;
&#xD;
        -  Patients: 80 patients with supracervical hysterectomy recruited at Tanta University&#xD;
           Hospital, gynecology clinics will be recruited according inclusion and exclusion&#xD;
           criteria. Inclusion criteria include all symptomatizing patients following supracervical&#xD;
           hysterectomy, of any age, of any complaints. The exclusion criteria were patients with&#xD;
           total hysterectomy, hysterectomies for malignant indications, and refusal to&#xD;
           participate.&#xD;
&#xD;
        -  Methods: All patients' demographic data, history, indication of hysterectomy, duration&#xD;
           since operation, postoperative complications and their main complaint.&#xD;
&#xD;
      Intervention: under general anesthesia cervical biopsy (4 quadrants) were taken from all&#xD;
      patients and was sent for histopathological examinations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients suffering after supracervical hysterectomy</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of cervical neoplasia or cancer incidence</measure>
    <time_frame>1 year</time_frame>
    <description>Detection of number of cases diagnosed with cervical Cervical intraepithelial neoplasia, or malignancy by histopathological examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of chronic cervicitis incidence</measure>
    <time_frame>1 year</time_frame>
    <description>Detection of number of cases diagnosed with inflammatory cells and other markers of inflammation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>CIN</condition>
  <condition>Cancer of Cervix</condition>
  <condition>Cervicitis</condition>
  <arm_group>
    <arm_group_label>Biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>four quadrant biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cervical biopsy</intervention_name>
    <description>4 quadrant biopsy</description>
    <arm_group_label>Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all symptomatizing patients following supracervical hysterectomy,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  with total hysterectomy,&#xD;
&#xD;
          -  hysterectomies for malignant indications,&#xD;
&#xD;
          -  refusal to participate.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ayman Shehata Dawood</name>
      <address>
        <city>Tanta</city>
        <state>Gharbia</state>
        <zip>31111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 13, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>April 4, 2021</last_update_submitted>
  <last_update_submitted_qc>April 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Ayman S Dawood, MD</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Uterine Cervicitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

